Enhanced Conolidine: Medical Scientist Clint Winters Announces Patent Filing on CONOCB2™, A Novel Conolidine Pain Relief Active Ingredient with Natural Endocannabinoids

ALPHARETTA, Ga., Jan. 11, 2022 /PRNewswire-PRWeb/ -- Winters Biotechnology has announced patent filings for CONOCB2™, a novel dietary ingredient featuring an enhanced version of the conolidine alkaloid formulated for greater natural pain relief.

This announcement comes on the heels of the patent filing for CONO1000™, the first ever natural conolidine ingredient to hit the world market.

For years, conolidine, a naturally occurring alkaloid found inside the bark of the Tabernaemontana divaricata tree, has been studied for its ability to effectively relieve pain.

A synthetic version of conolidine was initially investigated in 2011 and was compared therapeutically to morphine without exhibiting side effects or addiction risk in rat models.

In 2019, Australian scientists discovered it had similar pain-killing modalities as CBD.

Then in early 2021, scientists reconfirmed its ability to significantly relieve chronic pain as they pinpointed its ability to affect the ACKR3/CXCR7 receptor.

In 2017 Clint Winters became the first medical scientist in the world to explore the natural extraction of conolidine from the Tabernaemontana divaricata tree.

This extraction became public knowledge in 2019.

The evolution of these non synthetic conolidine ingredients have been under heavy testing by Winters Biotechnology for nearly 4 years.

There is strong evidence of it being a successful natural relief ingredient after private clinical testing involving nearly 30,000 voluntary users over multiple years.

In 2021, Clint Winters and Winters Biotechnology announced patents on a novel nutrient extraction system named the DualPolar™ extraction method, which is now being used to create a full-spectrum extraction of Tabernaemontana divaricata, including the conolidine alkaloid.

This extraction was named CONO1000™.

Conolidine CONOCB2™ is an enhanced version of CONO1000™ that has been formulated to also affect the endocannabinoid system in addition to the Opioid Receptors in the brain.

The purpose of the innovation is to create a "full spectrum' pain relief ingredient that will be highly effective against many types of common daily pain.

Clint Winters, now considered the world's leading authority on natural conolidine, had this to say about the new innovation.

"Developing CONO1000™ was one of the most rewarding experiences of my entire life. I have worked very hard to develop a natural version of this potent up and coming pain reliever. From day 1, I knew conolidine was special as it could provide safe and powerful relief to millions struggling with daily pain. With that said, I believe CONO1000™ is just the tip of the iceberg in conolidine innovations. My team and I immediately began investigating ways to make it even more active in the human body. We became very intrigued with the endocannabinoid system. That research led us to the development of CONOCB2™."

The endocannabinoid system is famously affected by cannabinoids found in hemp and cannabis, these cannabinoids are also known as CBD.

Clint Winters went on to say…

"Obviously there is evidence in regards to the endocannabinoid system and pain relief. This evidence is coupled with the current craze around CBD. With this in mind we felt adding the opioid receptor benefits of conolidine to endocannabinoid benefits could create a truly phenomenal relief ingredient that went to work fast and provided hours of full body relief."

The combination follows a scientific theory called the "entourage effect" in which multiple pain relieving ingredients combine to create a single super ingredient.

CONOCB2™ is a patent pending mix of CONO1000™ and naturally occurring endocannabinoids via fatty acids. Notably, Winters Biotechnology scientists sourced and added naturally occuring endocannabinoids avoiding cannabis and hemp. CBD is not present in CONOCB2™ in any form allowing it to be sold worldwide.

This formula also utilizes the powerful DualPolar™ extraction method during production.

Like CONO1000™, CONOCB2™ also includes 65 other naturally occurring alkaloids found in the potent Tabernaemontana divaricata plant and is now covered under a pending patent.

CONOCB2™ does not contain any banned ingredients nor does it contain hemp or cannabis in any form.

This innovation means that the potent conolidine alkaloid can work alongside naturally occuring endocannabinoids in a formula that is legal to use across the world.

Clint Winters went on to say,

"CONOCB2™ is the future of safe and natural pain relief. This "first of its kind" natural ingredient combines the power of naturally occurring conolidine and naturally occurring endocannabinoids in one powerful ingredient. In tests, we have been able to develop sublingual and topical applications with extraordinary efficacy. I have watched this powerful ingredient dramatically change lives in our private tests. I am excited to watch it help millions in the years to come as it becomes available worldwide as a legal pain relief ingredient"

Currently, CONO1000™ and CONOCB2™ are the first and only natural conolidine ingredients available in the world. Neither one has displayed any side effects.

Additionally, CONOCB2™ is the only known liquid relief ingredient that actively affects the endocannabinoid system without the use of hemp or cannabis.

Since it is not synthetic, CONOCB2™ will not require a prescription, making it available immediately to those in search of natural pain relief.

Winters Biotechnology is currently in discussions with multiple leading manufacturers regarding the production and distribution of CONO1000™ and CONOCB2™ .

This legal and powerful novel ingredient should be available worldwide by 2022 in all major world markets.

You can learn more about Clint Winters, Winters Biotechnology and CONOCB2™ by visiting WintersBiotechnology.com.

You can learn more about conolidine and CONOCB2 by visiting Conolidine.com.

Winters Biotechnology is a medical innovation firm based in Alpharetta, GA. The company is wholly owned by Private Equity Firm Winters Capital and was founded by medical scientist, entrepreneur, entertainment figure, and investor Clint Winters. The firm focuses on creating unique dietary ingredients and innovative nutraceutical and pharmaceutical manufacturing methods that manufacturers can license.

In addition to the CONO1000™ and CONOCB2™ patent filings, Mr. Winters has also filed two patents with the conolidine alkaloid natural pain killer and an additional patent in relation to the enhancement of CBD.

The firm is currently developing two novel drug delivery mechanisms that will be under patent by the end of the year.

Earlier in his career, Mr. Winters developed and patented a non-thermal infrared technology that is now being used for accelerated healing and pain relief.

Media Contact

Spencer Jargon, Winters Biotechnology, 1-877-678-9719, [email protected]

SOURCE Winters Biotechnology